Zengchun Hu | Anti-Tumor Therapy | Best Researcher Award

Published on by China Scientist

Prof. Dr. Zengchun Hu | Anti-Tumor Therapy | Best Researcher Award 

Zengchun Hu is a chief neurosurgeon and doctoral supervisor at The Second Affiliated Hospital of Dalian Medical University, specializing in the surgical and comprehensive treatment of gliomas, malignant brain tumors, and cerebrovascular diseases. A doctoral graduate in neurosurgery from Dalian Medical University, he further trained at Beijing Tian Tan Hospital to refine advanced surgical skills. He has contributed extensively to national research projects, published in leading SCI journals, and authored a neurosurgical textbook. His research explores lipid and sugar metabolism, ferroptosis, and targeted therapies in glioma and lung cancer, aiming to develop innovative treatment strategies that improve patient outcomes.

Prof. Dr. Zengchun Hu | The Second Affiliated Hospital of Dalian Medical University | China

Profile

SCOPUS

Education

  • Zengchun Hu earned his doctoral degree in neurosurgery from Dalian Medical University, establishing a strong foundation in surgical techniques and clinical neurology. He further enhanced his expertise through subspecialization training in neurosurgery at Beijing Tian Tan Hospital, where he refined advanced skills in managing complex neurological conditions. His academic journey combined rigorous research engagement with extensive clinical exposure, preparing him for a career at the forefront of neurosurgical innovation.

Experience

  • Currently serving as a chief neurosurgeon and doctoral supervisor at The Second Affiliated Hospital of Dalian Medical University, Zengchun Hu has built a reputation for his precision and dedication in neurosurgical care. He is highly experienced in performing surgeries for gliomas, malignant brain tumors, and cerebrovascular diseases. His surgical proficiency allows him to independently handle a large number of brain tumor operations annually. In addition to his clinical work, he has contributed to multiple national-level research projects and has authored numerous peer-reviewed articles in high-impact scientific journals.

Awards and Recognition

  • Zengchun Hu’s leadership in neurosurgery and his academic contributions have earned him recognition within both clinical and research communities. As the editor-in-chief of a specialized neurosurgical textbook published by Jilin Science and Technology Press, he has contributed to shaping the educational landscape for upcoming neurosurgeons. His appointment as an editorial board member for the Translational Medicine Electronic Journal and his role as a young editor further reflect his standing as a respected thought leader in his field.

Skills and Expertise

  • Zengchun Hu possesses exceptional skills in brain tumor surgery, cerebrovascular disease management, and advanced neurosurgical techniques. His expertise extends to integrating traditional and modern medical approaches in neurosurgical care. He is adept at leading multidisciplinary teams, mentoring doctoral candidates, and translating cutting-edge research findings into practical therapeutic strategies. His academic and clinical synergy ensures comprehensive patient care while advancing neurosurgical science.

Research Focus 

  • Zengchun Hu’s research is centered on the surgical and comprehensive treatment of gliomas and other malignant tumors. He investigates the mechanisms of lipid and sugar metabolism as well as ferroptosis in the development of gliomas and lung cancer. His studies have highlighted the therapeutic potential of targeting SVIP in glioblastoma progression and have revealed the anti-cancer effects of CPP through Nrf2 degradation and ferroptosis sensitization in non-small cell lung cancer. His work aims to develop novel therapeutic strategies that combine surgery with targeted molecular treatments to improve survival and quality of life for cancer patients.

Publications

  • Periplocin potentiates ferroptotic cell death in non-small cell lung cancer by inducing the degradation of Nrf2
    Authors: Jinhao Wang, Yue Zhu, Jialiang Song, Fengping Yang, Peng Wang, Ziyi Zhang, Yuxuan Li, Minghe Dai, Yinuo Wang, Waleed Yousuf, Jiayu Li, Dian Yang, Shaoxuan Cheng, Shuyan Liu, Zhaoxia Dai, Xun Qiu, Yingqiu Zhang, Zengchun Hu
    Journal: Cancer Cell International

  • Mechanism of microRNA-152-3p-Mediated Regulation of Autophagy and Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells
    Authors: Di Wu, Yang Zhang, Luna Zhang, Wanying Xia, Bingkun Cai, Feihong Dong, Ke Wu, Lichun Cheng, Mingkun Shao, Hui Ma, Zengchun Hu, Huiyi Lu
    Journal: OncoTargets and Therapy

  • SVIP reduces IGFBP-2 expression and inhibits glioblastoma progression via stabilizing PTEN
    Authors: Zixuan Wang, Xiaolong Qiao, Yinan Chen, Nan Peng, Chaoshi Niu, Yang Wang, Cong Li, Zengchun Hu, Caihua Zhang, Chuandong Cheng
    Journal: Cell Death Discovery

  • Pharmacological inhibition of the ubiquitin-specific protease 8 effectively suppresses glioblastoma cell growth
    Authors: Yu Long, Zengchun Hu, Dian Yang, Fuqiang Wang, Chen’ge Zhao, Yang Zhang, Yingqiu Zhang, Hui Ma, Huiyi Lv
    Journal: Open Life Sciences

  • Tanshinone IIA Microemulsion Protects against Cerebral Ischemia Reperfusion Injury via Regulating H3K18ac and H4K8ac In Vivo and In Vitro
    Authors: Hui Ma, Zeng-Chun Hu, Yu Long, Li-Chun Cheng, Chen-Yang Zhao, Ming-Kun Shao
    Journal: American Journal of Chinese Medicine

Conclusion

  • Through his combined roles as a surgeon, educator, and researcher, Zengchun Hu has established himself as a prominent figure in neurosurgery. His work reflects a dedication to improving surgical outcomes, advancing research in cancer treatment, and mentoring the next generation of neurosurgical specialists. By aligning clinical practice with scientific discovery, he continues to make a significant impact in both patient care and medical research.

Tongguo Shi | Cancer | Best Researcher Award

Published on by China Scientist

Dr. Tongguo Shi | Cancer | Best Researcher Award

Tongguo Shi is an Associate Researcher at the First Affiliated Hospital of Soochow University, specializing in cancer immunology and molecular medicine. He earned his PhD from Nanjing University in 2016 and has since focused on tumor immune evasion, immune checkpoint regulation, and colorectal cancer research. His work has been published in leading journals such as Cancer Immunology, Immunotherapy and Cell Death & Disease, with multiple studies highlighting novel therapeutic targets. With expertise in molecular biology and immunological assays, he is dedicated to advancing cancer immunotherapy and precision medicine.

Dr. Tongguo Shi | The First Affiliated Hospital of Soochow University | China

Profile

SCOPUS ID

ORCID ID

🎓Education

  • Tongguo Shi earned his PhD from Nanjing University in 2016, following his undergraduate studies at Liyi University, where he obtained a BA in 2010. His academic journey has equipped him with a strong foundation in medical and biological research, particularly in immunology and oncology.

👨‍🏫Experience

  • Currently serving as an Associate Researcher at the First Affiliated Hospital of Soochow University, Tongguo Shi has been contributing to medical research since December 2021. Prior to this role, he worked as a Research Associate at the same institution from 2017 to 2021, where he gained extensive experience in cancer immunology and molecular medicine. He also served as a Research Associate at the Center of Systems Medicine, Chinese Academy of Medical Sciences, from 2016 to 2017, further strengthening his expertise in cellular and molecular research.

🏆Awards and Recognitions

  • Throughout his career, Tongguo Shi has established himself as a leading researcher, contributing significantly to cancer immunotherapy and colorectal cancer studies. His role as a corresponding author in multiple high-impact journal publications highlights his expertise and recognition in the scientific community. His work on immunological mechanisms in cancer and inflammatory diseases has been widely cited, demonstrating the impact of his research.

💡Skills and Certifications

  • Tongguo Shi specializes in immuno-oncology, with a focus on tumor microenvironments, immune evasion mechanisms, and cancer immunotherapy. His research has explored the role of immune checkpoints such as B7-H3 and Tim-3 in colorectal and gastric cancers, as well as the impact of microRNAs on immune regulation in inflammatory diseases. His skills include molecular biology techniques, immunological assays, cancer cell signaling analysis, and translational research aimed at developing novel therapeutic strategies.

🔬 Research Focus

  • His research has led to groundbreaking findings on the interactions between immune cells and cancer cells, with a particular emphasis on T cell-mediated immune responses. He has published extensively in prestigious journals such as Cancer Immunology, Immunotherapy, Cell Death & Disease, Mucosal Immunology, and Gut, further advancing the understanding of cancer immunology and potential therapeutic interventions.

🌎Conclusion

  • Dr. Tongguo Shi exemplifies scientific excellence and collaborative leadership in cancer research. His work has significantly advanced the understanding of tumor immunology, cancer metabolism, and immunotherapy through high-impact interdisciplinary collaborations. His strong publication record, mentorship, and institutional partnerships highlight his commitment to groundbreaking discoveries that benefit both scientific progress and patient outcomes.

📖Publications

  • Elevated SPARC Disrupts the Intestinal Barrier Integrity in Crohn’s Disease by Interacting with OTUD4 and Activating the MYD88/NF‐κB Pathway
    Authors: J. Wang, Jiayu; Y. He, Yuxin; X. Zhu, Xingchao; J. Zhu, Jinghan; Z. Deng, Zilin; H. Zhang, Huan; Y. Chen, Yanjun; G. Zhang, Guangbo; T. Shi, Tongguo; W. Chen, Weichang
    Journal: Advanced Science, 2025

  • FASN Promotes Lipid Metabolism and Progression in Colorectal Cancer via the SP1/PLA2G4B Axis
    Authors: X. Liu, Xin; J. Lu, Jiachun; X. Ni, Xiangyu; Y. He, Yuxin; J. Wang, Jiayu; Z. Deng, Zilin; G. Zhang, Guangbo; T. Shi, Tongguo; W. Chen, Weichang
    Journal: Cell Death Discovery, 2025

  • Exploring the Link Between Noncoding RNAs and Glycolysis in Colorectal Cancer
    Authors: L. Xu, Liang; Y. Shen, Yu; C. Zhang, Chuanqiang; T. Shi, Tongguo; X. Sheng, Xuejuan
    Journal: Journal of Cellular and Molecular Medicine, 2025

  • The m6A Revolution: Transforming Tumor Immunity and Enhancing Immunotherapy Outcomes
    Authors: T. Shi, Tongguo; H. Zhang, Huan; Y. Chen, Yueqiu
    Journal: Cell & Bioscience, 2025

  • Exosome-Derived Proteins in Gastric Cancer Progression, Drug Resistance, and Immune Response
    Authors: J. Wang, Jiayu; H. Zhang, Huan; J. Li, Juntao; X. Ni, Xiangyu; W. Yan, Wenying; Y. Chen, Yueqiu; T. Shi, Tongguo
    Journal: Cellular & Molecular Biology Letters, 2024